{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:32:30Z","timestamp":1791513150723,"version":"4.3.4"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":396,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Tenofovir (TDF) is considered the ideal treatment for patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV). However, certain coinfected patients exhibit incomplete viral suppression, with persistent, and sometimes transient, bouts of HBV replication. The reasons for this, including clinical effect, are unclear. A total of 111 HIV-HBV-infected patients undergoing TDF-containing antiretroviral therapy were prospectively followed. Serum HBV-DNA viral load, hepatitis surface (HBsAg) and e antigen (HBeAg) status were obtained at baseline and every 6-12 months. Amino acid (aa) changes on the polymerase gene were assessed using direct sequencing after nested polymerase chain reaction in patients with persistent viremia (PV). After a median of 74.7 months (interquartile range: 33.4-94.7), virological response (VR; &lt;60 IU\/mL) occurred in 96 of 111 (86.5%) patients. Of these, 86 of 96 (89.6%) remained completely undetectable during follow-up (stabilized VR). The remaining 10 of 96 (10.4%) patients had a transient blip of detectable HBV-DNA (transient PV), during which time 9 of 9 (100%) with available samples had detectable plasma TDF. Low-level PV (LL-PV; 61-2,000 IU\/mL) was observed in 11 of 111 (9.9%) patients, the majority of which had detectable plasma TDF (8 of 9; 88.9%). High-level PV (&gt;2,000 IU\/mL) was rare (4 of 111; 3.6%) and was associated with nonadherence. At TDF initiation, patients with stabilized VR had significantly higher nadir CD4<jats:sup>+<\/jats:sup> count, compared to those with transient PV (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.006) or LL-PV (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04). No consistent aa changes, other than those associated with lamivudine resistance, were observed in patients with persistent viremia. Importantly, HBeAg loss, HBeAg seroconversion, and HBsAg loss only occurred in patients with stabilized VR. Two patients with stabilized VR developed hepatocellular carcinoma and 2 with LL PV died, 1 of a liver-related cause. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: Suboptimal HBV control during TDF treatment has a negative effect on serological outcomes, but not necessarily clinical events. Immunoregulation may provide more insight into this phenomenon. (Hepatology 2014;60:497\u2013507)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.27182","type":"journal-article","created":{"date-parts":[[2014,4,19]],"date-time":"2014-04-19T11:12:35Z","timestamp":1397905955000},"page":"497-507","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":76,"title":["Persistent viremia in human immunodeficiency virus\/hepatitis B coinfected patients undergoing long-term tenofovir: Virological and clinical implications"],"prefix":"10.1097","volume":"60","author":[{"given":"Anders","family":"Boyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Gozlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Maylin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Marie","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R1-11-20250207","doi-asserted-by":"crossref","first-page":"i47i58","DOI":"10.1136\/gutjnl-2012-302062","article-title":"HIV and viral hepatitis coinfections: advances and challenges.","volume":"61","author":"Lacombe","year":"2012","journal-title":"Gut"},{"key":"R3-11-20250207","doi-asserted-by":"crossref","first-page":"678686","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"R5-11-20250207","doi-asserted-by":"crossref","first-page":"12181229","DOI":"10.1053\/j.gastro.2010.06.042","article-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian metaanalyses.","volume":"139","author":"Woo","year":"2010","journal-title":"Gastroenterology"},{"key":"R6-11-20250207","doi-asserted-by":"crossref","first-page":"434442","DOI":"10.1002\/hep.26686","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.","volume":"59","author":"Kitrinos","year":"2014","journal-title":"Hepatology"},{"key":"R7-11-20250207","doi-asserted-by":"crossref","first-page":"e87e94","DOI":"10.1093\/cid\/cit002","article-title":"Patterns and causes of suboptimal response to tenofovirbased therapy in individuals coinfected with HIV and hepatitis B virus.","volume":"56","author":"Matthews","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"R8-11-20250207","first-page":"S112S122","article-title":"Management of treatment failure in chronic hepatitis B.","volume":"56","author":"Zoulim","year":"2012","journal-title":"J Hepatol"},{"key":"R9-11-20250207","doi-asserted-by":"crossref","first-page":"26572665","DOI":"10.1128\/JVI.02124-09","article-title":"No increase in hepatitis B virus (HBV)specific CD8 T cells in patients with HIV1HBV coinfections following HBVactive highly active antiretroviral therapy.","volume":"84","author":"Crane","year":"2010","journal-title":"J Virol"},{"key":"R10-11-20250207","doi-asserted-by":"crossref","first-page":"197205","DOI":"10.1097\/QAD.0b013e3283410ccb","article-title":"Increased intrahepatic apoptosis but reduced immune activation in HIVHBV coinfected patients with advanced immunosuppression.","volume":"25","author":"Iser","year":"2011","journal-title":"AIDS"},{"key":"R11-11-20250207","doi-asserted-by":"crossref","first-page":"93100","DOI":"10.1016\/j.antiviral.2012.12.007","article-title":"The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir.","volume":"97","author":"Qin","year":"2013","journal-title":"Antiviral Res"},{"key":"R12-11-20250207","first-page":"11581165","article-title":"The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigenpositive and hepatitis B e antigennegative hepatitis B virus strains.","volume":"49","author":"AminiBavilOlyaee","year":"2009","journal-title":"Hepatology"},{"key":"R13-11-20250207","doi-asserted-by":"crossref","first-page":"247254","DOI":"10.1136\/gut.2010.223206","article-title":"Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.","volume":"60","author":"Patterson","year":"2011","journal-title":"Gut"},{"key":"R14-11-20250207","doi-asserted-by":"crossref","first-page":"684695","DOI":"10.1016\/j.jhep.2013.05.038","article-title":"Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofoviremtricitabine combination or tenofovir monotherapy.","volume":"59","author":"Lavocat","year":"2013","journal-title":"J Hepatol"},{"key":"R15-11-20250207","doi-asserted-by":"crossref","first-page":"939949","DOI":"10.1097\/QAD.0b013e328352224d","article-title":"Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviralexperienced HIVhepatitis B virusinfected patients.","volume":"26","author":"Maylin","year":"2012","journal-title":"AIDS"},{"key":"R16-11-20250207","doi-asserted-by":"crossref","first-page":"419427","DOI":"10.1097\/01.aids.0000200537.86984.0e","article-title":"Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV.","volume":"20","author":"Lacombe","year":"2006","journal-title":"AIDS"},{"key":"R17-11-20250207","first-page":"167185","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection.","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"RU18-11-20250207","doi-asserted-by":"crossref","first-page":"661662","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009.","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"R19-11-20250207","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jchromb.2005.10.015","article-title":"Sensitive assay for determining plasma tenofovir concentrations by LCMSMS.","volume":"830","author":"Delahunty","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R20-11-20250207","doi-asserted-by":"crossref","first-page":"912922","DOI":"10.1002\/hep.26374","article-title":"High incidence of treatmentinduced and vaccineescape hepatitis B virus mutants among human immunodeficiency virushepatitis Binfected patients.","volume":"58","author":"Lacombe","year":"2013","journal-title":"Hepatology"},{"key":"R21-11-20250207","doi-asserted-by":"crossref","first-page":"10851089","DOI":"10.1016\/j.jhep.2003.09.022","article-title":"Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.","volume":"39","author":"Villeneuve","year":"2003","journal-title":"J Hepatol"},{"key":"R22-11-20250207","doi-asserted-by":"crossref","first-page":"217222","DOI":"10.1016\/j.jviromet.2003.10.002","article-title":"Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay.","volume":"115","author":"Deguchi","year":"2004","journal-title":"J Virol Methods"},{"key":"R23-11-20250207","doi-asserted-by":"crossref","first-page":"306311","DOI":"10.1016\/j.jcv.2012.12.022","article-title":"Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.","volume":"56","author":"Maylin","year":"2013","journal-title":"J Clin Virol"},{"key":"R24-11-20250207","first-page":"963974","article-title":"Liver fibrosis changes in HIVHBVcoinfected patients: clinical, biochemical and histological effect of longterm tenofovir disoproxil fumarate use.","volume":"15","author":"Boyd","year":"2010","journal-title":"Antivir Ther"},{"key":"R25-11-20250207","doi-asserted-by":"crossref","first-page":"158163","DOI":"10.1086\/426595","article-title":"Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.","volume":"40","author":"Maggiolo","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R26-11-20250207","doi-asserted-by":"crossref","first-page":"12161220","DOI":"10.1093\/infdis\/jit017","article-title":"Declining prevalence of HIV1 drug resistance in antiretroviral treatmentexposed individuals in Western Europe.","volume":"207","author":"De Luca","year":"2013","journal-title":"J Infect Dis"},{"key":"R27-11-20250207","doi-asserted-by":"crossref","first-page":"205212","DOI":"10.1111\/j.1365-2893.2011.01494.x","article-title":"Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs.","volume":"19","author":"Chotiyaputta","year":"2012","journal-title":"J Viral Hepat"},{"key":"R28-11-20250207","first-page":"991999","article-title":"Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response.","volume":"13","author":"RodriguezFrias","year":"2008","journal-title":"Antivir Ther"},{"key":"R29-11-20250207","first-page":"763773","article-title":"No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.","volume":"53","author":"SnowLampart","year":"2011","journal-title":"Hepatology"},{"key":"R30-11-20250207","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.3851\/IMP1940","article-title":"Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIVHBVcoinfected patients with delayed response to tenofovir.","volume":"17","author":"Lada","year":"2012","journal-title":"Antivir Ther"},{"key":"R31-11-20250207","first-page":"879886","article-title":"Trends in mortality after diagnosis of hepatitis B or C infection: 19922006.","volume":"54","author":"Walter","year":"2011","journal-title":"J Hepatol"},{"key":"R32-11-20250207","first-page":"507513","article-title":"Comparative risk of liverrelated mortality from chronic hepatitis B versus chronic hepatitis C virus infection.","volume":"55","author":"FaladeNwulia","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R33-11-20250207","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/j.1365-2893.2009.01146.x","article-title":"Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleosidenaive HBeAgpositive patients with chronic hepatitis B.","volume":"17","author":"Gish","year":"2010","journal-title":"J Viral Hepat"},{"key":"R34-11-20250207","doi-asserted-by":"crossref","first-page":"14431448","DOI":"10.1097\/QAD.0b013e32836011c2","article-title":"Tenofovir based combination therapy for HIVHBV coinfection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.","volume":"27","author":"Childs","year":"2013","journal-title":"AIDS"},{"key":"R35-11-20250207","doi-asserted-by":"crossref","first-page":"443451","DOI":"10.1002\/hep.24406","article-title":"Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response.","volume":"54","author":"Zoutendijk","year":"2011","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.27182","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201408000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:48:58Z","timestamp":1738946938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201408000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.27182","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}